Macomics is pleased to announce that Dr Lopez-Yrigoyen will Chair sessions at 2021 Tumour myeloid Microenvironment Directed Therapeutics Summit. She has extensive experience in genetic engineering/programming of human induced pluripotent stem cell derived macrophages and her sessions will highlight the advances and challenges in therapeutically targeting tumour-resident myeloid populations. The conference will be held virtually on March 16 – 18, 2021.
Author: edgover
Macomics secures £3.2 million seed funding
Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, launches today with a £3.2 million seed financing round led by transatlantic VC Epidarex Capital, with the Scottish Investment Bank, the investment arm of Scottish Enterprise, also investing.